Genetically Engineered Cells Resist Natural Killer Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The primary challenge in allogeneic cellular therapies is the host immune response against transplanted cells, leading to rejection and potential adverse reactions, which current strategies like immunosuppressive drugs and donor-recipient matching fail to adequately address, limiting therapeutic efficacy.
Innovation Solution
Engineered cells with heterologous nucleic acid sequences encoding polypeptides such as CLEC2D, TRAIL, and SERPINB9 to inhibit natural killer cell cytotoxicity, combined with genetic modifications like B2M attenuation, enhancing immune evasion and cell survival.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allogeneic cells are transplanted to treat diseases, then therapeutic benefit is improved, but host immune response causes cell rejection and adverse reactions
Solution Approach 1:
The patent applies this principle by engineering cells to express immune modulatory molecules (such as PD-L1, IDO1, TGF-β) that convert the harmful immune response into a beneficial state. These molecules actively suppress host immune rejection mechanisms, transforming the immune system from an adversary into a tolerant environment that supports allogeneic cell survival and function.
Solution Approach 2:
The patent uses immune modulatory molecules as intermediaries between the allogeneic cells and the host immune system. These molecules (e.g., PD-L1, IDO1, TGF-β) act as mediators that communicate with immune cells to suppress rejection responses, creating a buffer that allows therapeutic cells to survive without direct harmful interaction with the host immune system.
2Duration of action of stationary object
If immunosuppressive drugs are used to prevent rejection, then cell survival is improved, but side effects and complications increase
Solution Approach 1:
The patent applies self-service by engineering the therapeutic cells themselves to produce immune modulatory molecules (PD-L1, IDO1, TGF-β) that protect them from rejection. Instead of relying on external immunosuppressive drugs administered to the patient, the cells autonomously generate their own protective factors, eliminating the need for systemic immunosuppression and its associated side effects.
Solution Approach 2:
The patent inverts the conventional approach by instead of suppressing the immune system systemically with drugs, the therapeutic cells are engineered to actively modulate and suppress local immune responses against them. This reversal places the protective function within the therapeutic cells themselves rather than requiring external pharmacological intervention.
3Adaptability or versatility
If donor-recipient matching is performed to reduce rejection, then immune compatibility is improved, but treatment complexity and time increase
Solution Approach 1:
The patent fundamentally changes the parameter of immune compatibility from being determined by donor-recipient HLA matching to being determined by the expression level of engineered immune modulatory molecules (PD-L1, IDO1, TGF-β) on the therapeutic cells. This parameter change allows any donor cells to be compatible with any recipient by actively suppressing rejection through molecular expression rather than passive genetic matching.
Solution Approach 2:
The patent extracts the immune compatibility requirement from the complex donor-recipient matching process. By engineering cells to express immune modulatory molecules, the patent removes the need for extensive HLA typing, cross-matching, and compatibility assessment, simplifying the transplantation process while ensuring immune tolerance.
Data Source
AI summary
This disclosure provides methods and populations of cells, engineered to modulate the expression of select genes and thereby reduce natural killer cell mediated cytotoxicity. For example, this disclosure provides engineered cells equipped with one or more heterologous nucleic acid sequences encoding polypeptides that, when expressed, impede the typical cytotoxicity of natural killer cells as compared to comparable cell devoid of heterologous nucleic acid sequence.